accountof each of its product candidates and ARYx may have to alter its development and commercialization plans if collaborative relationships are not established for tecarfarin, budiodarone and ATI-7505, the risk that ARYx's product candidates may not...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to ARYx Therapeutics Aligns Operations to Development Activities
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
